Login to Your Account

Jazz inks $181M blood cancer deal with Pfenex

By Michael Fitzhugh
Staff Writer

Friday, July 29, 2016

Jazz Pharmaceuticals plc licensed global rights to several early stage blood cancer candidates from Pfenex Inc. in a deal that also included an option on an exclusive license for PF690.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription